EAACI CONGRESS 2016 – OVERVIEW SAT PROGRAMMES

line3

Allergy Therapeutics plc.
Sunday, 12 June 2016, 17:30 – 19:00
Hall B1

Adjuvants in Allergy: elevating efficacy

Ultra-short course immunotherapy
Ralph Mösges, Germany

Adjuvants in immunotherapy
Randolf Brehler, Germany

Future immunotherapy: virus like particles
Thomas Kündig, Switzerland

line3

Shire International GmbH
Sunday, 12 June 2016, 17:30 – 19:00
Hall B2

Improving Diagnosis: The Next Frontier in Hereditary Angioedema (HAE) Management

Chair:   Stephen Jolles, United Kingdom

Welcome, introductions and use of voting app
Stephen Jolles, United Kingdom

Diagnosing HAE patients today
Stephen Jolles, United Kingdom

Biomarkers: improving diagnosis
Marco Cicardi, Italy

Looking towards a future of improved risk stratification and management
Coen Maas, The Netherlands

Genetics: future diagnostics and the role of family testing
Faculty

Questions and discussion
All

Closing remarks
Stephen Jolles, United Kingdom

line3

DBV Technologies
Sunday, 12 June 2016, 17:30 – 19:00
Strauss 1+2

Epicutaneous Immunotherapy (EPIT): Bringing Innovation to the Treatment of Food Allergies

Welcome and Introductions
Hugh Sampson, United States

Food Allergy in Europe: Addressing an Unmet Medical Need
Jonathan Hourihane, Ireland

EPIT: A Novel Pathway to Treat Food Allergy
Christophe Dupont, France

Clinical Trial Results for the EPIT Patch in Food Allergy
Hugh Sampson, United States

Clinical Trial Experience With the EPIT Patch in Peanut Allergy: The Physician and Patient Perspective
Kari Nadeau, United States

Conclusions and Faculty Panel Discussion
Hugh Sampson, United States

line3

Stallergenes Greer
Sunday, 12 June 2016, 17:30 – 19:00
Strauss 3

Seizing opportunities to drive the change in AIT practice

Chair: Prof. P. Demoly, France

Introduction
M. Antonelli*, France

A vision for AIT: At the core of tomorrow’s allergy specialist practice
P. Demoly, France

A biotech approach: Quality is the very essence
P. Moingeon*, France

Committed to driving the change
M. Antonelli*, France

Conclusion and final remarks

Q&A session

*Stallergenes Greer

line3

FAES FARMA
Sunday, 12 June 2016, 17:30 – 19:00
Lehar 1

Setting safety as a benchmark

Chairs:
Antonella Muraro, Italy
Hans Ulrich Wahn, Germany

Ontogeny and the science of dosing in children
Martin Church, Germany

Model-based drug development: why focus on paediatrics?
Mónica Rodriguez, Spain

Paediatric allergic rhinitis and urticaria: the role of bilastine
Nikos Papadopoulos, Greece

Bilastine: the safety car
Ralph Mösges, Germany

line3

Teva Pharmaceuticals Europe BV
Sunday, 12 June 2016, 17:30 – 19:00
Lehar 2

Treating uncontrolled severe eosinophilic asthma now and in the future

Welcome and introduction
Leif Bjermer, Sweden

Unmet needs: rising to the challenge of uncontrolled severe asthma
Kai Beeh, Germany

Asthma phenotypes and biomarkers: can we predict treatment response?
Jan Lötvall, Sweden

Moving to the next level: targeting eosinophilic inflammation
Stephanie Korn, Germany

Reaching new horizons for our patients
All

Summary and close
Leif Bjermer, Sweden

line3

GLAXOSMITHKLINE
Monday 13 June 2016, 17:30 – 19:00
Hall B1

Evolving Treatment Options in Asthma

Chair: Neil Barnes, United Kingdom

Welcome and introduction
Neil Barnes, United Kingdom

Improving Asthma Management
Ronald Dahl, Denmark

Severe Asthma: An Emerging Role for Biomarkers
Andrew Greening, United Kingdom

Severe Refractory Eosinophilic Asthma: Impact of Mepolizumab
Peter Howarth, United Kingdom

Panel discussion chaired by Neil Barnes, United Kingdom

Close

line3

ALK
Monday 13 June 2016, 17:30 – 19:00
Strauss 1+2

The GAP trial – A landmark trial in childhood respiratory allergic disease

Chairs:
Erkka Valovirta, Finland
Waltraud Emminger, Austria

Can we stop the progression of childhood grass pollen allergy?
Ulrich Wahn, Germany

GAP trial design – introducing a new era of evidence
Graham Roberts, United Kingdom

GAP trial outcomes – asthma and rhinitis results
Henrik Jacobi, Denmark

Questions & Answers panel

line3

Nestlé Health Science
Monday 13 June 2016, 17:30 – 19:00
Strauss 3

Chair: Sibylle Koletzko, Germany

What can we Learn from Birth-cohorts? The GINI Study from Birth to 15 Years
Andrea von Berg, Germany

Diagnosing Cow’s Milk Protein Allergy, how big is the gap Between Medical Best-practice and Reality?
Sibylle Koletzko, Germany

The CoMiSS as a Predictor for the Diagnosis of Cow’s Milk Allergy
Yvan Vandenplas, Belgium

line3

LABORATORIOS LETI, S.L. unipersonal
Monday 13 June 2016, 17:30 – 19:00
Lehar 1

Facing allergy challenges with subcutaneous immunotherapy
Chair:   Oliver Pfaar, Germany

Subcutaneous immunotherapy for atopic dermatitis: safety and efficacy with depigmentedpolymerized extracts
Natalija Novak, Germany

Polysensitization: still a challenge in the treatments?
Victoria Cardona, Spain

Treatment of the respiratory allergy: the patient’s perspective
Otto Spranger, Austria

line3

AstraZeneca
Monday 13 June 2016, 17:30 – 19:00
Lehar 2

The Management of Uncontrolled Eosinophilic Asthma in the Era of Targeted Medicine

Chair: Giorgio Walter Canonica, Italy

Current Perspectives on Unmet Need and Heterogeneity of Uncontrolled Asthma
Pascal Chanez, France

The Biology and Role of Eosinophilis in Uncontrolled Asthma
Thomas B. Casale, United States

Emerging and Distinct Therapeutic Strategies for Eosinophilic Asthma
Giorgio Walter Canonica, Italy

line3

Aimmune Therapeutics
Tuesday 14 June 2016, 17:30 – 19:00
Strauss 3

Peanut Allergy Oral Immunotherapy: From Epidemiology to a Standardized Treatment Approach 

Opening Remarks
Anna H Nowak-Wegrzyn, United States

Epidemiology of Peanut Allergy
Ruchi Gupta, United States

Review of Academic OIT Clinical Trials
Kirsten Beyer, Germany

Safety and Efficacy Results From Aimmune’s Phase 2 Clinical Trials of Its’ Lead Investigational Product for the Treatment of Peanut Allergy
Andrew Bird, United States

Summation
Anna H Nowak-Wegrzyn, United States

Panel Discussion

Closing Remarks
Anna H Nowak-Wegrzyn, United States